Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Billing Codes · Pharmacy · PA · Pharmacy, Critical Care, Infectious Disease +2 moreMedium impact

08.00.85s, Tocilizumab and Related Biosimilars for Intravenous Infusion

Act
by Apr 1, 2026
Effective date
Apr 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross updated policy 08.00.85s to version 08.00.85u, adding three new HCPCS codes (M0233, M0234, Q0238) for tocilizumab-aazg biosimilar infusions in hospitalized COVID-19 patients. The policy designates tocilizumab-aazg (Tyenne) and tocilizumab-anoh (Avtozma IV) as preferred products, with nonpreferred products requiring prior documentation of contraindication, intolerance, or inadequate response to preferred options.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Apr 1, 2026 · 4 steps
01Billing team must update billing system to recognize and process new HCPCS codes M0233, M0234, and Q0238 for tocilizumab-aazg COVID-19 infusions in hospitalized patients.
02Configure system to flag claims using nonpreferred tocilizumab products (Actemra IV, Tofidence IV, other biosimilars) for prior authorization review, requiring documentation of contraindication, intolerance, or inadequate prior response to tocilizumab-aazg or tocilizumab-anoh.
03Update claim submission guidelines to reference preferred product hierarchy.
04Train billing and clinical staff on new code usage and product preferences.
If missed: Failure to implement preferred product edits may result in claim denials or delays for nonpreferred product utilization without required documentation.

Codes mentioned

M0233M0234Q0238J3262M0231M0232

Original notice

08.00.85s, Tocilizumab and Related Biosimilars for Intravenous Infusion
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.045q, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionMediumEffective Jul 1, 2026 · PharmacyMA08.045p, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionMediumEffective Apr 1, 2026 · Pharmacy08.00.85u, Tocilizumab and Related Biosimilars for Intravenous InfusionHighEffective Sep 14, 2026 · Pharmacy08.00.85t, Tocilizumab and Related Biosimilars for Intravenous InfusionMediumEffective Jul 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesPA policy changesPharmacyCritical CareInfectious DiseaseRheumatologyOncologyCode M0233Code M0234Code Q0238Code J3262Code M0231Code M0232

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account